CARsgen Therapeutics announced the opening of its new manufacturing facility in Shanghai.
The facility features capabilities to manufacture vectors and CAR-T cells to support CARsgen clinical programs. Upon completion of its final inspections, the 33,000-square-foot facility is expected to become China's first CAR-T cell manufacturing platform that is in strict compliance with current good manufacturing procedure (cGMP) regulations of China Food and Drug Administration (CFDA).
"This facility marks a significant milestone of CARsgen as it embedded our leading expertise and insights into CAR-T cell manufacturing,” Dr. Zonghai Li, President and CEO of CARsgen said. “We have already developed a strong CAR-T portfolio for treatment of many solid tumors including liver cancer, lung cancer, gastric cancer, pancreatic cancer, etc."
Founded in 2014, the company completed B series of financing of $30M in early 2016. Two of its CAR-T cell therapies, anti-GPC3 CAR-T for hepatocellular carcinoma (HCC) and cancer-specific anti-EGFR CAR-T for glioblastoma multiforme (GBM) have entered clinical trials.